A detailed history of Aqr Capital Management LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Aqr Capital Management LLC holds 26,090 shares of RCUS stock, worth $398,394. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,090
Previous 24,524 6.39%
Holding current value
$398,394
Previous $373,000 6.7%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$13.69 - $18.01 $21,438 - $28,203
1,566 Added 6.39%
26,090 $398,000
Q2 2024

Aug 14, 2024

BUY
$14.59 - $18.48 $144,674 - $183,247
9,916 Added 67.88%
24,524 $373,000
Q1 2024

May 15, 2024

BUY
$14.83 - $20.18 $54,292 - $73,878
3,661 Added 33.44%
14,608 $275,000
Q4 2023

Feb 14, 2024

BUY
$13.43 - $19.63 $147,018 - $214,889
10,947 New
10,947 $209,000
Q1 2023

May 15, 2023

BUY
$15.96 - $23.15 $1.6 Million - $2.32 Million
100,293 Added 82.91%
221,257 $4.04 Million
Q4 2022

Feb 14, 2023

BUY
$19.7 - $35.71 $16,863 - $30,567
856 Added 0.71%
120,964 $2.5 Million
Q3 2022

Nov 14, 2022

BUY
$23.23 - $30.07 $1.16 Million - $1.5 Million
49,775 Added 70.77%
120,108 $3.14 Million
Q2 2022

Aug 15, 2022

BUY
$17.23 - $37.73 $1.21 Million - $2.65 Million
70,333 New
70,333 $1.78 Million
Q4 2021

Feb 14, 2022

SELL
$31.38 - $48.47 $184,169 - $284,470
-5,869 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$26.93 - $37.68 $855,566 - $1.2 Million
-31,770 Reduced 84.41%
5,869 $205,000
Q2 2021

Aug 16, 2021

SELL
$22.75 - $35.77 $218,104 - $342,926
-9,587 Reduced 20.3%
37,639 $1.03 Million
Q1 2021

May 17, 2021

SELL
$26.16 - $41.39 $490,238 - $775,648
-18,740 Reduced 28.41%
47,226 $1.33 Million
Q4 2020

Feb 16, 2021

BUY
$17.0 - $32.36 $8,942 - $17,021
526 Added 0.8%
65,966 $1.71 Million
Q3 2020

Nov 16, 2020

BUY
$17.14 - $25.47 $124,744 - $185,370
7,278 Added 12.51%
65,440 $1.12 Million
Q2 2020

Aug 17, 2020

BUY
$13.97 - $36.56 $449,638 - $1.18 Million
32,186 Added 123.91%
58,162 $1.44 Million
Q1 2020

May 15, 2020

SELL
$8.78 - $19.28 $8,525 - $18,720
-971 Reduced 3.6%
25,976 $361,000
Q4 2019

Feb 14, 2020

BUY
$7.33 - $10.79 $197,521 - $290,758
26,947 New
26,947 $272,000

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.1B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.